Management of Moderate to Severe Fatty Liver Disease

Risk Stratification

• Patients with moderate to severe fatty liver disease should be stratified based on fibrosis risk using the FIB-4 score, with scores less than 1.3 indicating low risk, 1.3-2.67 indicating intermediate risk, and greater than 2.67 indicating high risk, according to the American Gastroenterological Association 1, 2
• Liver stiffness measurement by transient elastography can also be used to stratify patients, with values less than 8.0 kPa indicating low risk, 8.0-12.0 kPa indicating intermediate risk, and greater than 12.0 kPa indicating high risk, as recommended by the American Gastroenterological Association 1, 2
• Patients with intermediate or high risk should be referred to hepatology for specialized management, as suggested by the American Gastroenterological Association 1, 3
• Patients with liver stiffness measurement of 20 kPa or higher, or those with thrombocytopenia, should undergo screening for gastroesophageal varices, according to the American Gastroenterological Association 1

Lifestyle Interventions

• A weight loss of 5-10% is recommended to improve steatosis and fibrosis, with 5% weight loss improving steatosis and 7-10% weight loss improving steatohepatitis and fibrosis, as suggested by the American Gastroenterological Association 4, 5
• A Mediterranean diet is strongly recommended, featuring daily consumption of vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil, as recommended by the American Gastroenterological Association 4, 6, 5
• Limiting simple sugars, red meat, processed meats, and ultra-processed foods is also recommended, according to the American Gastroenterological Association 4, 5, 2
• A hypocaloric diet with a 500-1000 kcal deficit per day can help achieve a weight loss of 500-1000g per week, as suggested by the American Gastroenterological Association 5
• At least 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity exercise per week is recommended, as suggested by the American Gastroenterological Association 6, 2
• Complete abstinence from alcohol is recommended, as even low alcohol intake can double the risk for adverse liver-related outcomes in patients with non-alcoholic fatty liver disease, according to the American Gastroenterological Association 4, 6

Pharmacological Management

• Statins are safe and effective for managing dyslipidemia in patients with fatty liver disease, as recommended by the American Gastroenterological Association 6, 2
• Optimizing management of comorbidities, such as tight glycemic control for patients with diabetes and blood pressure control for hypertensive patients, is also important, according to the American Gastroenterological Association 2
• Avoiding medications that may worsen steatosis, such as corticosteroids, amiodarone, methotrexate, and tamoxifen, is recommended, as suggested by the American Gastroenterological Association 2

Monitoring and Follow-up

• Low-risk patients should have annual follow-up with repeated non-invasive tests, such as FIB-4 and liver stiffness measurement, as recommended by the American Gastroenterological Association 1, 7
• Intermediate and high-risk patients should have more frequent monitoring, every 6 months, with liver function tests and non-invasive fibrosis markers, according to the American Gastroenterological Association 1, 2
• Patients with cirrhosis should have regular screening for hepatocellular carcinoma and gastroesophageal varices, as recommended by the American Gastroenterological Association 1

Common Pitfalls to Avoid

• Neglecting cardiovascular risk assessment is a common pitfall, as cardiovascular disease is the main driver of mortality in patients with non-alcoholic fatty liver disease before cirrhosis develops, according to the American Gastroenterological Association 7
• Failing to address all components of metabolic syndrome can worsen liver disease progression, as suggested by the American Gastroenterological Association 2

Risk of Fibrosis in Grade 3 Fatty Liver Disease

Understanding the Distinction Between Steatosis Grade and Fibrosis Stage

• The presence of NASH (steatosis plus hepatocyte ballooning and lobular inflammation) is the key driver of fibrosis progression, not the steatosis grade itself, with fibrosis progressing more rapidly in patients with steatohepatitis than in those with simple steatosis alone 8
• Grade 3 steatosis is defined as ≥67% of hepatocytes containing fat, which is separate from fibrosis staging that ranges from F0 (no fibrosis) to F4 (cirrhosis) 9, 10

Quantifying the Risk Based on Fibrosis Stage

• F0-F2 (early fibrosis) has a very low incidence of hepatocellular carcinoma and liver-related events 9, 10
• F2 or higher (clinically significant fibrosis) is an independent predictor of liver-related complications and mortality 8, 11
• F4 (cirrhosis) has more than 1.5% annual incidence of hepatocellular carcinoma, with significantly reduced transplant-free survival 9, 10

Risk Stratification Strategy for Grade 3 Steatosis

• The American Gastroenterological Association recommends non-invasive fibrosis assessment for all patients with grade 3 steatosis, using FIB-4 score and transient elastography (liver stiffness measurement) 11

Management Based on Risk Stratification

• For intermediate/high-risk patients (FIB-4 ≥1.3 or LSM ≥8.0 kPa), hepatology referral is recommended for consideration of liver biopsy to confirm NASH and stage fibrosis, with target 7-10% weight loss to improve steatohepatitis and achieve fibrosis improvement 9, 10, 8, 11
• For patients with advanced fibrosis (F3) or cirrhosis (F4), hepatocellular carcinoma surveillance every 6 months with ultrasound is recommended, as well as screening for gastroesophageal varices if LSM ≥20 kPa or thrombocytopenia is present 9, 10

Critical Lifestyle Interventions to Prevent Fibrosis Progression

• Complete smoking cessation is mandatory, as smoking increases hepatocellular carcinoma risk by 1.5-1.8 times and is associated with liver fibrosis, according to the American College of Gastroenterology 9, 10

Management of Metabolic Comorbidities

• Statins are safe and strongly recommended for dyslipidemia management in all NAFLD patients, reducing hepatocellular carcinoma risk by 37% in meta-analyses, as suggested by the American Association for the Study of Liver Diseases 9, 10
• Avoid metformin alternatives that increase hepatocellular carcinoma risk, such as sulfonylureas and insulin, as recommended by the European Association for the Study of the Liver 9, 10, 8

Management of Grade 3 Fatty Liver Disease

Lifestyle Modifications

• A 5-7% weight loss reduces intrahepatic fat content and inflammation in patients with grade 3 fatty liver disease, according to the American Association for the Study of Liver Diseases 12, 13
• A 7-10% weight loss is required to improve steatohepatitis and achieve fibrosis regression in patients with grade 3 fatty liver disease, as recommended by the American Association for the Study of Liver Diseases 12, 13
• The Mediterranean diet is the most evidence-based approach for patients with grade 3 fatty liver disease, with daily vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil, as suggested by the European Association for the Study of the Liver 14
• A caloric deficit of 500-1000 kcal/day reduction is recommended for patients with grade 3 fatty liver disease, typically 1,200-1,500 kcal/day for women and 1,500-1,800 kcal/day for men, according to the American Association for the Study of Liver Diseases 12
• At least 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity exercise per week is recommended for patients with grade 3 fatty liver disease, as suggested by the American Association for the Study of Liver Diseases 13

Special Considerations for Severe Obesity

• Bariatric surgery should be considered for patients with severe obesity and grade 3 fatty liver disease who meet national eligibility criteria, as recommended by the European Association for the Study of the Liver 14
• Bariatric surgery can resolve NASH in 85% of patients at 1 year post-surgery, improve steatosis in 88%, steatohepatitis in 59%, and fibrosis in 30%, according to the European Association for the Study of the Liver 14
• Bariatric surgery is safe even in patients with cirrhosis, as suggested by the European Association for the Study of the Liver 14

Pharmacologic Treatment for Liver Disease

• Pioglitazone (30-45 mg/day) can improve steatohepatitis in patients with biopsy-proven NASH, though fibrosis improvement data are limited, as suggested by the American Association for the Study of Liver Diseases 13
• Vitamin E (800 IU/day) can be considered in non-diabetic patients with biopsy-proven NASH, but use caution in those with prostate cancer, according to the American Association for the Study of Liver Diseases 13